Holen Sie sich die Stockscreener-App
6.46
21.03%
-1.72
Handel nachbörslich:
6.53
0.07
+1.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.18
Offen:
$7.42
24-Stunden-Volumen:
2.70M
Relative Volume:
1.71
Marktkapitalisierung:
$601.07M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-4.9692
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-20.54%
1M Leistung:
-19.85%
6M Leistung:
-14.55%
1J Leistung:
-63.77%
1-Tages-Spanne:
$6.20
$7.59
1-Wochen-Bereich:
$6.20
$8.38
52-Wochen-Spanne:
$3.76
$19.60
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.46 | 761.11M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
565.24 | 212.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
213.83 | 151.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.12 | 57.84B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
146.08 | 41.02B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.96 | 36.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Myriad Genetics (NASDAQ:MYGN) Releases Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
TD Cowen Raises Myriad Genetics (MYGN) Price Target to $9.00 | M - GuruFocus
Why Myriad Genetics (MYGN) Stock Is Down Today - TradingView
UBS Maintains Neutral Rating and Raises PT for Myriad Genetics ( - GuruFocus
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds - TradingView
How institutional ownership impacts Myriad Genetics Inc. stockInflation Watch & Low Risk High Win Rate Picks - newser.com
Has Myriad Genetics Inc. found a price floorMarket Activity Summary & Daily Momentum Trading Reports - newser.com
What earnings revisions data tells us about Myriad Genetics Inc.2025 Top Decliners & Daily Profit Focused Screening - newser.com
Will Myriad Genetics Inc. stock beat EPS estimates2025 Market Overview & Accurate Buy Signal Alerts - newser.com
Published on: 2025-11-04 03:54:27 - newser.com
Will Myriad Genetics Inc. bounce back from current supportBull Run & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-11-04 01:15:36 - newser.com
Myriad Genetics Q3 2025 slides: volume growth offsets revenue decline, CCC strategy advances By Investing.com - Investing.com South Africa
Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
Earnings call transcript: Myriad Genetics Q3 2025 sees revenue beat, stock rises - Investing.com Philippines
Myriad Genetics Inc (MYGN) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... - Yahoo Finance
Myriad Genetics Q3 2025 Earnings Call Transcript - MarketBeat
Myriad Genetics Q3 2025 slides: volume growth offsets revenue decline, CCC strategy advances - Investing.com Nigeria
Myriad Genetics (MYGN) Reports Strong Q3 Revenue and Strategic D - GuruFocus
Myriad: Q3 Earnings Snapshot - CTPost
Myriad Genetics (MYGN) Reaffirms FY25 Revenue and EBITDA Projections - GuruFocus
Myriad Genetics Outpaces Expectations But Faces Profit Challenges - Finimize
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3 - Yahoo Finance
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops - Yahoo Finance
Myriad Genetics Inc. Q3 Loss Climbs - Nasdaq
Myriad Genetics Inc Reports Q3 2025 Revenue of $205.7 Million, S - GuruFocus
Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing - TradingView
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution - The Manila Times
Myriad Genetics Reports Third Quarter 2025 Financial Results, Announces Strategic Collaboration with SOPHiA GENETICS - Quiver Quantitative
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial ... - Bluefield Daily Telegraph
How to use a screener to detect Myriad Genetics Inc. breakoutsJuly 2025 Rallies & Verified Entry Point Detection - newser.com
Is Myriad Genetics Inc. stock attractive for long term wealth buildingPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Advanced analytics toolkit walkthrough for Myriad Genetics Inc.Portfolio Performance Summary & Low Risk Entry Point Guides - newser.com
What’s the recovery path for long term holders of Myriad Genetics Inc.July 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Myriad Genetics Inc. stock trendline breakdown2025 Price Momentum & Reliable Trade Execution Plans - newser.com
What momentum shifts mean for Myriad Genetics Inc.Quarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Myriad Genetics Q3 2025 Earnings Preview - MSN
How to recover losses in Myriad Genetics Inc. stockJuly 2025 Summary & Stock Timing and Entry Methods - newser.com
Will Myriad Genetics Inc. stock continue dividend increasesWeekly Market Summary & Fast Entry High Yield Tips - newser.com
Can Myriad Genetics Inc. stock rebound after recent weaknessJuly 2025 Closing Moves & Proven Capital Preservation Tips - newser.com
Can Myriad Genetics Inc. (MYD) stock deliver strong annual returnsJuly 2025 Volume & Comprehensive Market Scan Reports - newser.com
Myriad Genetics (MYGN) Set to Release Q3 Earnings - GuruFocus
Candlestick signals on Myriad Genetics Inc. stock todayJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Published on: 2025-11-02 12:00:00 - newser.com
EBITDA per share of Myriad Genetics, Inc. – BX:MYD - TradingView
Will Myriad Genetics Inc. (MYD) stock gain from lower interest rates2025 Dividend Review & Fast Momentum Stock Entry Tips - newser.com
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings - Yahoo Finance
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
6.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):